RU2464026C2 - Лечение лейкемии, устойчивой к иматинибу, с применением 4-аминохинолина-3-карбонитрила - Google Patents

Лечение лейкемии, устойчивой к иматинибу, с применением 4-аминохинолина-3-карбонитрила Download PDF

Info

Publication number
RU2464026C2
RU2464026C2 RU2009144128/15A RU2009144128A RU2464026C2 RU 2464026 C2 RU2464026 C2 RU 2464026C2 RU 2009144128/15 A RU2009144128/15 A RU 2009144128/15A RU 2009144128 A RU2009144128 A RU 2009144128A RU 2464026 C2 RU2464026 C2 RU 2464026C2
Authority
RU
Russia
Prior art keywords
leukemia
bcrabl
compound
methoxy
positive
Prior art date
Application number
RU2009144128/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2009144128A (ru
Inventor
Беккер ХЬЮЗ (US)
Беккер ХЬЮЗ
Original Assignee
Вайет Ллс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2464026(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Вайет Ллс filed Critical Вайет Ллс
Publication of RU2009144128A publication Critical patent/RU2009144128A/ru
Application granted granted Critical
Publication of RU2464026C2 publication Critical patent/RU2464026C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2009144128/15A 2007-06-01 2008-05-30 Лечение лейкемии, устойчивой к иматинибу, с применением 4-аминохинолина-3-карбонитрила RU2464026C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
US60/932,650 2007-06-01

Publications (2)

Publication Number Publication Date
RU2009144128A RU2009144128A (ru) 2011-07-20
RU2464026C2 true RU2464026C2 (ru) 2012-10-20

Family

ID=39639071

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009144128/15A RU2464026C2 (ru) 2007-06-01 2008-05-30 Лечение лейкемии, устойчивой к иматинибу, с применением 4-аминохинолина-3-карбонитрила

Country Status (23)

Country Link
US (1) US11103497B2 (cg-RX-API-DMAC7.html)
EP (4) EP2777704A3 (cg-RX-API-DMAC7.html)
JP (3) JP5888853B2 (cg-RX-API-DMAC7.html)
KR (1) KR101493543B1 (cg-RX-API-DMAC7.html)
CN (1) CN101686973B (cg-RX-API-DMAC7.html)
AU (1) AU2008260070B9 (cg-RX-API-DMAC7.html)
BR (1) BRPI0812355A2 (cg-RX-API-DMAC7.html)
CA (3) CA2688467C (cg-RX-API-DMAC7.html)
CL (1) CL2008001577A1 (cg-RX-API-DMAC7.html)
CY (2) CY1115251T1 (cg-RX-API-DMAC7.html)
DK (2) DK2478905T3 (cg-RX-API-DMAC7.html)
ES (2) ES2881391T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055524T2 (cg-RX-API-DMAC7.html)
IL (1) IL202407A0 (cg-RX-API-DMAC7.html)
MX (1) MX2009013069A (cg-RX-API-DMAC7.html)
PA (1) PA8782301A1 (cg-RX-API-DMAC7.html)
PL (2) PL3002009T3 (cg-RX-API-DMAC7.html)
PT (2) PT3002009T (cg-RX-API-DMAC7.html)
RU (1) RU2464026C2 (cg-RX-API-DMAC7.html)
SI (2) SI3002009T1 (cg-RX-API-DMAC7.html)
TW (1) TW200908982A (cg-RX-API-DMAC7.html)
WO (1) WO2008150957A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200908480B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
JP6026441B2 (ja) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited キナーゼ阻害剤としてのアミノキノリン
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
AR092530A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de amino-quinolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
CN105143208B (zh) 2013-02-21 2017-09-26 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的喹唑啉
KR101733665B1 (ko) * 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 F1 또는 Rg3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにtdp-43に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用
EP4746884A2 (en) * 2023-07-21 2026-05-27 Icahn School of Medicine at Mount Sinai G9a/glp inhibitors and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006124863A2 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors
RU2292202C2 (ru) * 2001-01-25 2007-01-27 Бристол-Маерс Сквибб Компани Способы введения аналогов эпотилона при лечении рака

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
EP2341133A1 (en) 2001-10-05 2011-07-06 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
CA2543163A1 (en) 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
TW200724548A (en) 2005-04-25 2007-07-01 Pfizer Antibodies to myostatin
AU2006270187A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant SRC kinase polypeptides
KR101135220B1 (ko) 2005-10-06 2012-04-24 일라이 릴리 앤드 캄파니 항-마이오스타틴 항체
WO2007056177A2 (en) * 2005-11-04 2007-05-18 Bristol-Myers Squibb Pharma Company T315a and f317i mutations of bcr-abl kinase domain
EP2777704A3 (en) * 2007-06-01 2015-01-21 Wyeth LLC Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2292202C2 (ru) * 2001-01-25 2007-01-27 Бристол-Маерс Сквибб Компани Способы введения аналогов эпотилона при лечении рака
WO2006124863A2 (en) * 2005-05-16 2006-11-23 Irm Llc Pyrrolopyridine derivatives as protein kinase inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PUTTINI М. et al. In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Ingibitor, against Imatinib-Resistant Src-Abl Neoplastic Cells // Cancer Res 2006; 66: 11314-11322. JABBOUR E. et al. New Targeted Therapies for Chronic Mielogenous Leukemia: Opportuniti to Overcome Imatinib Resistance // Semin Hematol 44 (suppl 1) 2007: 25-31. *
ВОЛКОВА M.A. Хронический миелолейкоз. Гл.17. Клиническая онкогематология. - М.: Медицина, 2001, с.237-262. *

Also Published As

Publication number Publication date
EP2478905A2 (en) 2012-07-25
HUE055524T2 (hu) 2021-11-29
RU2009144128A (ru) 2011-07-20
CY1124391T1 (el) 2022-07-22
EP3002009B1 (en) 2021-07-07
CN101686973A (zh) 2010-03-31
JP2014111629A (ja) 2014-06-19
CA2964162A1 (en) 2008-12-11
EP3002009A3 (en) 2016-07-06
AU2008260070B2 (en) 2011-08-18
DK2478905T3 (da) 2014-06-30
IL202407A0 (en) 2010-06-30
EP2777704A2 (en) 2014-09-17
PT3002009T (pt) 2021-08-02
AU2008260070A1 (en) 2008-12-11
EP2478905A3 (en) 2013-01-16
HK1142812A1 (en) 2010-12-17
CN101686973B (zh) 2013-06-19
PA8782301A1 (es) 2009-01-23
WO2008150957A3 (en) 2009-08-06
US11103497B2 (en) 2021-08-31
ZA200908480B (en) 2010-08-25
AU2008260070B9 (en) 2012-01-19
US20080318971A1 (en) 2008-12-25
JP5888853B2 (ja) 2016-03-22
TW200908982A (en) 2009-03-01
PL2478905T3 (pl) 2014-10-31
WO2008150957A2 (en) 2008-12-11
BRPI0812355A2 (pt) 2015-01-27
CA2964162C (en) 2019-12-31
CY1115251T1 (el) 2017-01-04
EP2777704A3 (en) 2015-01-21
SI2478905T1 (sl) 2014-07-31
DK3002009T3 (da) 2021-08-02
ES2881391T3 (es) 2021-11-29
CA2688467C (en) 2015-05-12
JP2010529038A (ja) 2010-08-26
EP2152267A2 (en) 2010-02-17
KR101493543B1 (ko) 2015-02-13
JP2016074700A (ja) 2016-05-12
CL2008001577A1 (es) 2008-07-25
PL3002009T3 (pl) 2021-12-13
EP2478905B1 (en) 2014-05-14
CA2868899A1 (en) 2008-12-11
EP3002009A2 (en) 2016-04-06
CA2868899C (en) 2017-06-13
SI3002009T1 (sl) 2021-09-30
PT2478905E (pt) 2014-07-16
KR20100017983A (ko) 2010-02-16
CA2688467A1 (en) 2008-12-11
MX2009013069A (es) 2010-03-17
ES2477567T3 (es) 2014-07-17

Similar Documents

Publication Publication Date Title
US11103497B2 (en) Treatment of imatinib resistant leukemia
CN119733053A (zh) Kras g12c抑制剂与米托蒽醌的药物组合及其用途
JP6728072B2 (ja) mdm2阻害剤の間欠投与
JP2021121611A (ja) アピリモドを用いる癌の処置方法
US20170079972A1 (en) Novel ros1 inhibitor and its use
CN115006397A (zh) 一种预防或治疗肿瘤疾病的药物用途
SG11202107488PA (en) Methods of treating breast cancer with tucatinib
US7417148B2 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
US20250161276A1 (en) Drug combinations and methods of treating ovarian cancer
KR102798463B1 (ko) 페로켈라타아제 억제제 및 사용 방법
HK1142812B (en) Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles
US20050032904A1 (en) Composition and use of allylamine derivatives
EP4452275A1 (en) Combination of cisplatin and elimusertib for the treatment of pediatric liver cancers
AU2024206169A1 (en) Raf inhibitor and kras g12c inhibitor combination therapy
Veale et al. Rupal Jivan, Jade Peres 2, Leonard Howard Damelin 3, 4, Reubina Wadee 5